DexCom, Inc. (NASDAQ:DXCM) Q3 2024 Earnings Call Transcript October 24, 2024 4:30 PM ET
Company Participants
Sean Christensen - VP, Finance and IR
Kevin Sayer - President and CEO
Jereme Sylvain - CFO
Conference Call Participants
Danielle Antalffy - UBS
Larry Biegelsen - Wells Fargo
Matt Taylor - Jefferies
Jeff Johnson - Baird
Robbie Marcus - JPMorgan
Joanne Wuensch - Citibank
Michael Polark - Wolfe Research
Mathew Blackman - Stifel
Travis Steed - Bank of America
Marie Thibault - BTIG
Matthew O'Brien - Piper Sandler
Bill Plovanic - Canaccord Genuity
Jayson Bedford - Raymond James
Joshua Jennings - TD Cowen
Shagun Singh - RBC Capital Markets
Chris Pasquale - Nephron Research
Mike Kratky - Leerink Partners
Steve Lichtman - Oppenheimer
Patrick Wood - Morgan Stanley
Issie Kirby - Redburn-Atlantic
Macauley Kilbane - William Blair
Operator
Ladies and gentlemen, welcome to the DexCom Third Quarter 2024 Earnings Release Conference Call. My name is Abby, and I will be your operator for today's call. At this time, all participants are in a listen-only mode, and later we will conduct a question-and-answer session. [Operator Instructions] As a reminder, the conference is being recorded. And I will now turn the call over to Sean Christensen, Vice President, Finance and Investor Relations. Mr. Christensen, you may begin.
Sean Christensen
Thank you, Abby, and welcome to DexCom's third quarter 2024 earnings call. Our agenda begins with Kevin Sayer, DexCom's Chairman, President and CEO, who will summarize our recent highlights and ongoing strategic initiatives, followed by a financial review and outlook from Jereme Sylvain, our Chief Financial Officer. Following our prepared remarks, we will open the call up for your questions. At that time, we ask analysts to limit themselves to one question each, so we can provide an opportunity for everyone participating today. Please note that there are also slides available related to our third quarter 2024 performance on the DexCom Investor Relations website on the Events and Presentations page.
With that, let's review our safe harbor statement. Some of the statements we will make on today's call may constitute forward-looking statements. These statements reflect management's intentions, beliefs and expectations about future events, strategies, competition, products, operating plans and performance. All forward-looking statements included on this call are made as of the date hereof based on information currently available to DexCom are subject to various risks and uncertainties and actual results could differ materially from those anticipated in the forward-looking statements. The factors that could cause actual results to differ materially from those expressed or implied by any of these forward-looking statements are detailed in DexCom's annual report on Form 10-K, most recent quarterly report on Form 10-Q, and other filings with the Securities and Exchange Commission.